The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

IV.a

Bronchospasm - Wheezing - Asthma

The asthma may not be a class effect, being sometimes specific to a given anti-TNF agent, the patient not reacting to another anti-TNF drug (PMID 18443165). The asthma may survive drug discontinuance

Publications

Torres T, Vilaça S, Velho G, Selores M

Etanercept-induced asthma in a psoriatic patient resolving with transition to ustekinumab.

European journal of dermatology : EJD 2012 Sep-Oct;22;696-7 — 2012 Sep-Oct — 696-7

Guilleminault L, Carré P, Beau-Salinas F, Taillé C, Dieudé P, Crestani B, Diot P, Marchand-Adam S

Asthma unmasked with tumor necrosis factor-?-blocking drugs.

Chest 2011 Oct;140;1068-1071 — 2011 Oct — 1068-1071

Dubey S, Kerrigan N, Mills K, Scott DG

Bronchospasm associated with anti-TNF treatment.

Clinical rheumatology 2009 Aug;28;989-92 — 2009 Aug — 989-92

Janssen R, Krivokuca I, Kruize AA, Koenderman L, Lammers JW

Adalimumab-induced bronchospasm: not a class effect.

Thorax 2008 May;63;472-3 — 2008 May — 472-3